Translumina has announced the launch of Vivo Isar, its latest generation dual drug polymer-free coated stent, in various International markets including Europe.
According to a press release issued by the company, Vivo Isar is the first dual drug polymer-free coronary stent technology, which brings together a stent with a superior safety profile without compromising the drug release kinetics. Vivo Isar is the first technology that uses Probucol, the company adds, an antioxidant and lipid-lowering drug, as a carrier for releasing Sirolimus and thus creates a polymer-free drug-eluting stent platform with uncompromised safety and efficacy.
In 2020, Translumina published 10-year follow-up data on its dual drug polymer-free coated stent, which were released in the Journal of the American College of Cardiology (JACC).
“The ten-year outcome of Vivo Isar is a major breakthrough in drug-eluting stent technology as it proves that synthetic polymers can be removed from a drug-eluting stent without compromising the efficacy of the drug-eluting stent. The excellent safety profile demonstrated in the 10-year follow-up study is especially notable as it provides a powerful new technology for treating complex coronary artery disease in high-risk patient subsets. This drug-eluting stent technology carries the great potential of significantly shortening the duration of dual antiplatelet therapy,” said Adnan Kastrati, (German Heart Center, Munich, Germany) and the lead investigator of ISAR TEST 5, the trial that compared Vivo Isar to Endeavour Resolute (Medtronic).
“We are very pleased to be able to provide our premium high-quality stents to customers across the globe. Cardiologists world over now have a choice to give a proven and safer drug-eluting stent to their patients who otherwise have poorer outcomes with conventional drug-eluting stent, more so among the high-risk diabetic subset,” said Gurmit Singh Chugh, co-founder of Translumina.
